November 18, 2019

TissueTech Announces Appointment of New Chief Commercial Officer

Thomas (Tom) Williamson tapped to provide strategic oversight of sales and marketing as the company continues to expand its commercialization efforts

Miami, Fla. – November 18, 2019 – TissueTech, Inc., a pioneer in the development and clinical application of regenerative human birth tissue products marketed through its subsidiaries BioTissue, Inc. and Amniox Medical, Inc., announced this week the appointment of Tom Williamson to the position of Chief Commercial Officer (CCO) to support the continued strategic expansion of its marketing, sales and commercial operations.

Williamson will oversee all commercial scaling efforts to further drive adoption of the BioTissue and Amniox umbilical cord and amniotic-membrane based products while leading the company’s marketing strategies to attain enterprise-wide growth.

“Tom has the depth of experience necessary to help us build on our momentum and plan for new commercial opportunities in the years ahead. His appointment represents a significant enhancement to our leadership team,” said Amy Tseng, TissueTech President and Chief Executive Officer.  “He is a strategic leader with a proven track record in executing market expansions and accelerating revenue growth.  We look forward to his contributions.”

Williamson brings over 20 years of management experience in commercial sales and marketing to TissueTech as a member of the Executive Team. He has demonstrated success in territory development, sales growth, team leadership, mentoring and development, and strategic account management. He has had consistent success in executing market expansion, accelerating revenue growth, and building successful organizations.

Prior to joining TissueTech, he was Chief Commercial Officer at BioStable Science & Engineering. He has held several notable leadership roles throughout his career including Vice President, Commercial Operations and Vice President, Sales at Entellus Medical, which sold to Stryker Corporation for $662m in 2018.

A native of New Orleans, Tom obtained his Bachelor of Science degree in chemical engineering at Louisiana State University.

“I am excited to join TissueTech and work closely with the Executive Leadership Team to build a best-in-class global commercial organization,” said Williamson. “TissueTech is the scientific leader in the human birth tissue-based biologics industry and regenerative medicine.  It is this leadership position that drew me to TissueTech and will help the organization transcend through its next phase of growth.”

About TissueTech, Inc.

TissueTech, Inc., the parent company of Amniox Medical, Inc. and BioTissue, Inc., pioneered the development and clinical application of human placental tissue-based products. Founded in 1997, BioTissue markets products for the ophthalmology and optometry markets; and Amniox markets products for use in the musculoskeletal and wound care markets. Clinicians have performed more than 500,000 human implants with the company’s products and published more than 360 peer-reviewed studies supporting its technology platform. The Company’s first product, AmnioGraft®, is the only tissue graft designated by the FDA to act as an anti-scarring, anti-inflammatory and anti-angiogenic agent and supporting epithelial adhesion and differentiation. Learn more at

Related Content